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Abstract
Anxiety-like behaviors are integral features of withdrawal from chronic ethanol exposure. In the
experiments in the current study, we tested the hypothesis that anxiety can be regulated independently
of other withdrawal signs and thus may be responsive to selective pharmacological agents. For 17
days, rats were fed ethanol (8–12 g/kg/day) in a liquid diet. Between 5 and 6 h after cessation of
ethanol treatment, rats were tested in either the social interaction or plus-maze test of anxiety-like
behavior after treatment with drugs hypothesized to have anxiolytic action. SB242084, flumazenil,
and CRA1000—antagonists for 5-hydroxytryptamine (serotonin) (5-HT) 2C (5-HT2C),
benzodiazepine, and corticotropin-releasing factor type 1 (CRF1) receptors, respectively—attenuated
decreased social interaction without concomitant effects on activity measures. In contrast, ifenprodil,
MDL 72222, and zolpidem—antagonists for N-methyl-D-aspartate (NMDA) and 5-HT3 receptors,
and agonist for benzodiazepine type 1 receptors, respectively—did not share this effect. Results for
SB242084, flumazenil, and ifenprodil in the elevated plus-maze test were comparable to those in the
social interaction test. These results support the suggestion that multiple neuronal systems (CRF1,
5-HT2C, and benzodiazepine receptors) contribute to the ethanol withdrawal sign of decreased social
interaction. Furthermore, the selective effects of pharmacological agents on social interaction seem
to indicate that this behavior can be dissociated from other signs. Because anxiety may be a
complicating factor in alcohol withdrawal and relapse, future studies of this type are needed to provide
focus for the effort to define selective and novel antianxiety agents for these disorders.
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Studies of antianxiety-like actions of pharmacological agents in animals undergoing ethanol
withdrawal are challenging, in part because of the co-occurrence of potentially confounding
signs, such as tremor, suppressed activity/locomotion, and seizures. Nonetheless, the results
of many previous reports show that withdrawal from chronic ethanol treatment results in
anxiety-like behavior in both human beings (Koob & Le Moal, 1997; Meyer, 1986; Naranjo
& Sellers, 1985) and animal models (Baldwin et al., 1991; Criswell & Breese, 1993; File et
al., 1989; Knapp et al., 1998; Moy et al., 1997, 2000). The mechanisms mediating anxiety-like
behavior have not been definitively established.
Although benzodiazepines such as diazepam have long been known to be helpful in attenuating
anxiety during ethanol withdrawal, it is generally understood that significant tolerance and
dependence may result from their use. Novel benzodiazepine agents are actively being pursued
as possibly safer treatments [see, for example, June et al. (1998a, 1998b)]. Like
benzodiazepines, agents directed at the N-methyl-D-aspartate (NMDA) receptor [e.g.,
dizocilpine maleate (MK-801)] have also met with difficulties, given evidence for
neurotoxicity or lack of efficacy on anxiety-like behavior (Criswell et al., 1994; Gatch et al.,
1999; Horváth et al., 1997). However, NMDA receptor-modulatory sites (e.g., ifenprodil
binding site or the strychnine-insensitive glycine recognition site) may present safer and more
promising targets (Snell et al., 2000; Yang et al., 1996). Novel agents acting on corticotropin-
releasing factor type 1 (CRF1), 5-hydroxytryptamine (serotonin) (5-HT) 2C (5-HT2C), or 5-
HT 1A (5-HT1A) receptors (Chaki et al., 1999; File et al., 1993b; Griebel et al., 1997; Kennett
et al., 1996, 1997; Schaffer & Naranjo, 1998; Wood et al., 2001) also offer promise for safely
attenuating the anxiety of ethanol withdrawal. For example, the 5-HT1A receptor agonist
buspirone has made the transition from animal studies (File et al., 1993b; Lal et al., 1991) to
human beings and is recommended for treatment of chronic anxiety in alcoholism (Schaffer
& Naranjo, 1998).
In the current series of experiments, we tested potential antianxiety agents, acting at a range
of neurotransmitter receptors (CRF1, 5-HT2C, and 5-HT3 receptors; the benzodiazepine type
1 receptor; and the polyamine-site on the NMDA receptor), in a modification of the social
interaction test. The social interaction test is a simple and elegant animal model that has been
used in studies of a host of anxiogenic or anxiolytic drugs of various classes [see, for example,
Costall et al. (1988), Dunn et al. (1989), File et al. (1996, 1999), and Overstreet et al. (2000)]
and ethanol or benzodiazepine withdrawal [see, for example, Andrews et al. (1997), File
(1997), File et al. (1989, 1993a, 1993b), and Kampov-Polevoy et al. (2000)]. In the current
studies, we attempted (1) to assess anxiety-like behavior with the social interaction test after
withdrawal from shorter-term ethanol drinking (17 days), in which low-to-moderate levels of
ethanol withdrawal severity are manifest; (2) to confirm the induction of anxiety-like behavior
with a second established animal model; and (3) to determine whether this approach could
generate anxiety-like behavior that was separable (operationally/pharmacologically) from
effects of ethanol withdrawal on locomotor behavior. These objectives were based, in part, on
the premise that anxiety exists in various forms that are differentially elicited in different
anxiety models and that manipulation of specific receptors in brain can alter the expression of
specific anxiety states. Positive results from this type of behavioral study would set the stage
for future complementary studies to identify neuroanatomic substrates of the anxiety
component of withdrawal and effective pharmacological actions.
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2. Materials and methods
2.1. Subjects
For 1 week before ethanol treatment, groups of 40, adult male, Sprague–Dawley rats (each
weighing between 160 and 180 g), purchased from Charles River (Raleigh, NC), had ad libitum
access to food and water in a temperature-and humidity-controlled environment on a normal
12-h light/12-h dark cycle, with lights on at 0900. For each group of 40 rats, 8 received control
diet, and 32 received an ethanol-containing diet. After receiving this diet for 17 days, the rats
were withdrawn and treated with vehicle or one of several treatments described below. Animal
care and use was approved by the Institutional Animal Care and Use Committee at the
University of North Carolina as per the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research
Council, 1996).
2.2. Drug treatments
Ethanol (from 95% stock; Aaper, Shelbyville, KY) was administered by means of a
nutritionally complete liquid diet. This standard dietary ethanol procedure involves
administration of 7% [weight/volume (wt./vol.)] ethanol in a lactalbumin/dextrose-based diet
for 17 days, during which time rats generally consume ethanol at 8 to 12 g/kg/day and achieve
blood ethanol levels up to 200 mg/dl (Criswell & Breese, 1993; Frye et al., 1981; Knapp et al.,
1998). The diet was nutritionally complete (with concentrations of vitamins, minerals, and
other nutrients derived from ICN Research Diets) and calorically balanced (with dextrose)
across ethanol-treated rats and control rats. Intake matching was achieved by giving the control
diet–treated rats a volume of diet equivalent to the average intake of the ethanol diet–treated
rats the day before. Both groups readily gained weight during the ethanol exposure period.
In the first series of experiments, specific receptor antagonist or agonist treatments were given
after removal of chronic ethanol diet exposure on day 17. Each rat received only one of the
drugs and was tested only one time during withdrawal. The maximal withdrawal syndrome
resulting from this procedure (including anxiety-like behavioral responses) occurs 5 to 7 h after
removal of the ethanol diet from the rats’ cages (Criswell & Breese, 1993; Knapp et al.,
1998; Moy et al., 2000). Attempts to block behavioral changes induced by withdrawal during
this period were made with intraperitoneal injections of the 5-HT2C receptor antagonist
SB242084 (6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy) pyridin-3-yl carbomyl]
indoline) (Smith-Kline Beecham, Harlow, UK); the 5-HT3 receptor antagonist MDL 72222
(3-tropanyl-3,5-dichlorobenzoate); the NMDA receptor antagonist ifenprodil (2-(4-benzyl-
piperidino)-1-(4-hydroxyphenyl)-1-propanol) (Research Biochemicals International, Natick,
MA); the nonpeptide CRF antagonist CRA1000•H2SO4 (2-[N-(2-methylthio-4-
isopropylphenyl)-N-ethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridin-1-yl]-6-
methylpyrimidine) (Taisho Pharmaceutical Co., Ltd., Omiya, Japan); the benzodiazepine
receptor antagonist flumazenil (RO15-1788, Hoffman-La Roche Inc., Nutley, NJ); and the
benzodiazepine type 1 receptor agonist zolpidem (Synthelabo Recherche, Cedex, France).
SB242084 (1 mg/kg), flumazenil (5 mg/kg), CRA1000 (1 mg/kg), and MDL 72222 (1 mg/kg)
were prepared as fine suspensions after sonication in a 0.5% solution of
carboxymethylcellulose (CMC), whereas ifenprodil (5 mg/kg) was prepared in distilled water.
Zolpidem (3 mg/kg) was dissolved in saline. All drugs were administered as a 2-ml/kg dose
between 5 and 6 h into withdrawal and 7 min (flumazenil), 15 min (zolpidem), or 30 min
(CRA1000, SB242084, ifenprodil, and MDL 72222) before behavioral testing. All doses of
drugs were carefully chosen on the basis of evidence of anxiolytic activity in other models or
on the basis of information documenting the highest doses that one could expect would limit
sedative or other generally disruptive effects on rat behavior (Criswell & Breese, 1993; Ebert
et al., 1997; Harro et al., 2001; Mazzola-Pomietto et al., 1995; Millan et al., 2001; Moy et al.,
Knapp et al. Page 3













1997, 1998). To confirm drug effects and dose responsivity, these doses were tested in a
replication experiment with additional doses as follows: ifenprodil, 2.5, 5.0, and 10.0 mg/kg;
zolpidem, 1.5 and 3.0 mg/kg; MDL 72222, 0.3, 1.0, and 3.0 mg/ kg; flumazenil, 1.25, 2.50,
and 5.00 mg/kg; CRA1000, 0.25, 0.50, and 1.00 mg/kg; SB242084, 0.25, 0.50, and 1.00 mg/
kg. To determine the potential effects of these drugs in non–ethanol-treated rats, select doses
of drugs were examined as follows in a final experiment: SB242084, 1 mg/kg; CRA1000, 1
mg/kg; flumazenil, 5 mg/kg; and ifenprodil, 5 mg/kg.
2.3. Behavioral testing
The primary behavioral test of anxiety used was the social interaction test (Duxon et al.,
1997; File et al., 1996, 1999; File & Hyde, 1977; Gonzalez et al., 1996). Between 5 and 6 h
into withdrawal, two identically treated pairs of rats, naive to the test and approximately equal
in body weight, were placed into the center of a test box (a 60 × 60-cm square open field with
16 15 × 15-cm squares marked on the floor) simultaneously for a 5-min period. The time each
rat engaged in social interaction (conspecific grooming, sniffing, following, crawling over/
under) with its partner was recorded by an observer blind to the treatment conditions. Increased
anxiety was inferred from reduced social interaction times. Locomotor activity, recorded as
the number of squares entered during the 5-min session, was also recorded. It is important to
emphasize that, unlike the plus-maze test behavior, all behavioral subcomponents of social
interaction except “following” are independent of forward locomotion. Thus, when social
interaction is present the animals tend to stay within the same square or two. Then, when a
bout of interaction ends animals may or may not ambulate from square to square. Furthermore,
results of other recent work in this laboratory have established that social interaction behavior
within rat pairs was not correlated (Overstreet et al., 2002), a finding that reflects the fact that
one animal may be actively engaged in a particular behavior such as grooming while the other
is not. On the basis of these observations, as well as analyses with the use of individual animal
data or data representing the combined data from the pair give comparable results (Overstreet
et al., 2003), scores from individual rats were used in all analyses.
A second behavioral test of anxiety, the elevated plus-maze, was used in a subgroup of rats
immediately before the social interaction test (Moy et al., 1997; Pellow et al., 1985). Rats were
placed in the maze for 5 min and scored for the number of entries into and time spent in the
open arms of the maze. Locomotor activity in the maze was determined from the number of
closed-arm entries (File et al., 1999; Pellow et al., 1985), whereas the measure of anxiety-like
behavior was inferred from diminished time in the open arms (Gonzalez et al., 1998).
2.4. Statistical analysis
Social interaction time in seconds and the number of squares entered are normally distributed
scores. Therefore, data were analyzed by analysis of variance (ANOVA). A similar strategy
was used for plus-maze test data, on which analyses were conducted of the closed-arm entries
and the time in open arms. When significant, Tukey tests were used to compare pairs of groups
(n = 8–10).
3. Results
3.1. Experiment 1: effect of ethanol withdrawal on social interaction and locomotor activity
Rats experiencing ethanol withdrawal consistently reduced their time in social interaction
across all experiments in the current study. Normally, rats engaged in 30 to 40 s of social
interaction during the 5-min test period (Fig. 1), whereas ethanol-withdrawn rats typically
displayed only 5 to 10 s of this behavior [t(18) = 6.19, P < .001]. Ethanol withdrawal also
reduced locomotor activity (Fig. 1), as reflected in lower numbers of squares entered during
the social interaction test [t(18) = 3.22, P < .01]. However, the reduction in social interaction
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was not simply a consequence of the decreased locomotor activity, because the groups were
still different when the scores for social interaction and locomotor activity were compared as
a ratio. Rats that received control diet had a ratio of 0.32, whereas those exposed to the ethanol
diet had ratios of only 0.18 (indicating that the withdrawal preferentially affected the social
interaction measure). A different profile of drug action emerged for effects on locomotor
activity.
3.2. Experiment 2: effect of flumazenil, SB242084, and ifenprodil on social interaction,
locomotor activity, and plus-maze test behavior
The initial series of pharmacological manipulations comparing results with the social
interaction test revealed specific receptor-dependent and behavior-dependent effects during
ethanol withdrawal. Among the group differences in the social interaction test [F(4,36) = 10.29,
P < .0001], the benzodiazepine antagonist flumazenil and the 5-HT2C receptor antagonist
SB242084 attenuated ethanol withdrawal–induced deficits in social interaction time (P < .05
vs. vehicle; Fig. 2). This effect was also observed when ratios of social interaction to locomotor
activity were compared (data not shown). In contrast, the NMDA receptor antagonist ifenprodil
exerted a limited effect in the social interaction test (Fig. 2; P > .05 vs. vehicle). In the social
interaction test, a significant group effect on the locomotor activity measure was found [Fig.
2; F(4,36) = 5.05, P < .005]. Drug effects on social interaction were not accompanied by
reduction of activity deficits. The pattern of results in the plus-maze test experiment mirrored
the social interaction results (Fig. 3). For example, significant differences were found in open-
arm time [F(4,31) = 5.31, P < .005] and closed-arm entries [F(4,31) = 7.49, P < .001] among
treatment groups. Ethanol withdrawal reduced the number of closed-arm entries and the
amount of time that the rats spent in the open arms by 57% and 76%, respectively (Fig. 3).
Flumazenil and SB242084 were active in the test, but ifenprodil was not.
3.3. Experiment 3: effects of MDL 72222, CRA1000, and ifenprodil on social interaction and
locomotor activity
Given the parallel pharmacological profiles of behavioral activity in the social interaction test
and the plus-maze test, other agents were examined only in the social interaction test. Among
the group differences seen during withdrawal [F(4,33) = 18.93, P < .0001], the CRF1 receptor
antagonist CRA1000 attenuated social interaction deficits (P < .05 vs. vehicle; Fig. 4). The 5-
HT3 receptor antagonist MDL 72222 did not attenuate social interaction deficits (P > .05 vs.
vehicle; Fig. 4). In the social interaction test, a significant group effect on the locomotor activity
measure was found [Fig. 4; F(4,33) = 10.99, P < .0001]. Drug effects on social interaction were
not accompanied by reduction of activity deficits.
3.4. Experiment 4: effect of flumazenil, zolpidem, and ifenprodil on social interaction and
locomotor activity
The ameliorative effects of flumazenil on social interaction deficits were again revealed (P < .
05 vs. vehicle) among the group effects [F(4,34) = 11.85, P < .0001] in Experiment 4 (Fig. 5).
The benzodiazepine type 1 receptor agonist zolpidem did not attenuate social interaction
deficits in this experiment (P > .05 vs. vehicle; Fig. 5). In the social interaction test, a significant
group effect on the locomotor activity measure was found [Fig. 5; F(4,34) = 5.43, P < .005].
Drug effects on social interaction were not accompanied by reduction of activity deficits.
3.5. Effect of study drugs in control rats not exposed to ethanol
In control rats that had not been exposed to ethanol, no significant effect of the drugs on social
interaction behavior was observed, with the exception of ifenprodil, which reduced social
interaction behavior (Table 1). Ifenprodil and flumazenil significantly attenuated locomotor
behavior in control rats, but CRA1000 and SB242084 did not (Table 1).
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3.6. Evaluation of multiple drug doses
In corroboration of the single-dose study results, MDL 72222 and zolpidem were also not active
at any dose when evaluated in multiple-dose experiments (Table 2) and were not pursued
further. The lack of effect of ifenprodil in the social interaction test was replicated at three
different doses (Table 2). Flumazenil, CRA1000, and SB242084 reversed withdrawal-induced
deficits in social interaction time, as in the single-dose experiments (Table 2). The most robust
effects were observed at the highest doses of these drugs.
4. Discussion
The replicated results from experiments in the current study demonstrate that a model
incorporating relatively short-term (17 days) dietary ethanol intake and the social interaction
test can be used to study anxiety-like behavior during ethanol withdrawal in rats. These results
also demonstrate that pharmacological blockade of 5-HT2C, CRF1, or benzodiazepine
receptors, but not blockade of 5-HT3 or stimulation of specific benzodiazepine type 1 receptors,
during withdrawal from ethanol can attenuate anxiety-like responding in the relative absence
of drug effects on withdrawal-induced suppression of general locomotor activity. The
independence of locomotor activity from anxiety-like responding observed in the experiments
in the current study supports previous findings in this model [Breese et al. (online publication
10 July 2003 at http://www.acnp.org/citations/Npp07100303159/default.pdf); Overstreet et al.
(2002, 2003)]. Thus, anxiety-like behavior can be manipulated in a sign-specific manner in the
social interaction test. These results emphasize the importance of breaking down the
withdrawal syndrome into its respective signs for study and intervention. The findings should
promote efforts to develop pharmacotherapies for specific ethanol withdrawal signs that
otherwise may independently promote further cycles of intake and withdrawal.
The role of benzodiazepine receptors in the expression of anxiety-like behavior during ethanol
withdrawal was consistently shown in the results of previous experiments [see, for example,
Criswell & Breese (1993), File et al. (1992), Jung et al. (2000), and Moy et al. (1997, 2000)].
However, a general agonist action at benzodiazepine receptors may be insufficient to
encompass the relevant mechanisms operating in the current experiments. For example,
gamma-aminobutyric acid B (GABAB) receptors may also be engaged at this time because
baclofen antagonized ethanol withdrawal–induced deficits in behavior in social interaction and
plus-maze tests (File et al., 1991, 1992). With regard to GABAA receptors, zolpidem
preferentially binds to α1 GABA subunit–containing receptors (benzodiazepine type 1
receptors) (Doble, 1999; Mereu et al., 1990), an effect that may bias zolpidem’s behavioral
actions toward sedation rather than anxiolysis (McKernan et al., 2000). This action of zolpidem
differs from that of the classic benzodiazepines, which are less specific. However, previous
study findings from our laboratory showed that zolpidem possesses anxiolytic activity in the
elevated plus-maze during withdrawal, and other study findings showed that zolpidem
possesses this behavioral action in normal (control) animals as well [see, for example, Griebel
et al. (1996) and Pellow and File (1986)]. Because the ethanol withdrawal–induced social
interaction deficits were somewhat less severe in the first zolpidem experiment (i.e., 47%
reduction), it is possible that the potential anxiolytic action of zolpidem might have been more
apparent against a typical background of more severe deficits (70%–90% reductions).
However, in the replication experiment, the more typical withdrawal deficit was not blocked
by either of two doses tested. Thus, that zolpidem is apparently not clinically useful in human
beings for anxiety, is sedative at higher doses, and is not active against social interaction deficits
during ethanol withdrawal underscore the potential importance of the actions of flumazenil
and benzodiazepine type 2 agents in the anxiety associated with alcoholism.
Because the anxiolytic action of benzodiazepines in both control and withdrawn animals is
most likely related to their ability to enhance GABA function in key brain regions, one might
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predict that the benzodiazepine antagonist flumazenil would have no effect on, or perhaps
would exacerbate, anxiety-like behavior during withdrawal. However, in the current study and
other studies [see, for example, Criswell & Breese (1993), File et al. (1989, 1992), and Moy
et al. (1997, 2000)], flumazenil blocked anxiety-like behavior in different tests involving
different withdrawal paradigms. These findings argue for a second mechanism of action,
perhaps related to the blockade of endogenous benzodiazepine inverse agonists that may be
present at the benzodiazepine receptor at this time (Buck et al., 1991; File et al., 1989; Moy et
al., 1997, 2000). This effect is interesting in light of the fact that flumazenil has a half-life of
16 min (Lister et al., 1984) and yet can reduce anxiety-like behavior of ethanol withdrawal
when administered many hours or days before a single withdrawal (Buck et al., 1991; File et
al., 1989) or during multiple withdrawals before a final withdrawal (Knapp et al., 2001). This
persistent effect of flumazenil in the absence of drug underscores the possibility that an
important and persistent ethanol-dependent phenomenon is at work that may relate to specific
interactions with the rich structural and functional diversity of GABA and benzodiazepine
receptors. The inactivity of zolpidem in the current experiments also supports the suggestion
of involvement of non-type 1 benzodiazepine receptors in this flumazenil effect, which was
most marked at higher doses. It is known that various binding sites have differential affinities
for and responses to flumazenil (Barnard et al., 1998), and potential structural adaptations of
GABA receptors in select cells or brain regions after chronic ethanol treatment [see, for
example, Grobin et al. (2000), Papadeas et al. (2001), and Petrie et al. (2001)] may mediate
these differences. Furthermore, results of the dose-ranging and drug-treated control
experiments demonstrate that the antianxiety actions during withdrawal can occur without
correcting locomotor deficits in the plus-maze or social interaction test or without having
actions on anxiety in control animals. One can propose, then, that flumazenil and the
endogenous inverse agonists that it may block [e.g., octadecaneuropeptide (ODN), diazepam
binding inhibitor (DBI), or triakontatetraneuropeptide (TTN)] compete for unique receptor
sites differentially in chronic ethanol–treated versus control states. This proposition may be
particularly important if it can be shown that these endogenous benzodiazepines have
preferential actions on benzodiazepine type 2 receptors.
The potential role of 5-HT in ethanol withdrawal–associated anxiety was supported in previous
reports (Gatch et al., 2000; Lal et al., 1993; Overstreet et al., 2000; Prather et al., 1991; To et
al., 1999). Results of experiments in the current study extend previous research findings by
showing an impressive ability of the selective 5-HT2C receptor antagonist SB242084 to
ameliorate deficits in social interaction and plus-maze open-arm time induced by ethanol
withdrawal. Moreover, the drug was without significant effect on either locomotor activity or
social interaction in control rats. In the plus-maze test, reduced locomotor activity (reduced
closed-arm entries) arguably complicates the selectivity of the test for anxiety-like behavior
during withdrawal. However, that both SB242084 and flumazenil were shown to increase the
time in open arms despite the ethanol-induced reduction in closed-arm entries supports the
suggestion that the anxiety-like behavior is to a significant extent independent of the locomotor
activity. In other studies, lower doses of the 5-HT2C receptor agonist m-chlorophenylpiperazine
(mCPP) were required to induce a maximum anxiogeniclike response in ethanol-withdrawn
rats relative to control rats (Rezazadeh et al., 1993). Together, these results seem to indicate
that 5-HT2C receptors, perhaps in the amygdala [see Pompeiano et al. (1994)], may play an
important role in the expression of the anxiety-like signs of ethanol withdrawal. These results
are also consistent with the proposed role for 5-HT2A/2C receptor–mediated protein kinase C
(PKC)/phosphoinositide (PI) signaling in ethanol dependence (Pandey, 1998; Pandey &
Pandey, 1996).
The failure of the 5-HT3 receptor antagonist MDL 72222 to block social interaction deficits
supports the suggestion that these receptors are not involved significantly in the expression of
anxiety-like behavior during ethanol withdrawal. However, because this 5-HT3 receptor
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antagonist blocked anxiety-like behavior in other contexts (Bilkei-Gorzó et al., 1998; Higgins
et al., 1991) and chronic treatment with another 5-HT3 antagonist, ondansetron, attenuated
social interaction deficits in ethanol-withdrawn rats (Costall et al., 1990), there seem to be
specific complex actions of 5-HT at this receptor that as yet need to be resolved. One could
argue that the anxiolytic dose range of this drug may not include the dose used in the current
study. However, evidence seems to indicate that higher doses can be sedative (Mazzola-
Pomietto et al., 1995). Therefore, it is unlikely that MDL 72222 could reverse social interaction
deficits in this model. Overall, these observations of SB242084 and MDL 72222 seem to
indicate that the action of 5-HT during ethanol withdrawal on anxiety-like behavior may
depend on the 5-HT receptor subtype and the subtype of anxiety-like behavior assessed in
different tests.
Overactivity of the CRF system in anxiety occurring during ethanol withdrawal, as well as in
non–ethanol-treated animals, has been implicated in a number of studies. Alcohol or a peptide
CRF antagonist attenuates CRF-induced or withdrawal-induced anxiety-like behavior
(Baldwin et al., 1991; Thatcher-Britton & Koob, 1986). Results of similar studies support the
suggestion that amygdala CRF may play an important role in this effect (Menzaghi et al.,
1994; Merlo Pich et al., 1995; Rassnick et al., 1993). Results of the current studies are consistent
with those findings, in that the novel selective nonpeptide CRF1 receptor antagonist CRA1000
(Chaki et al., 1999; Okuyama et al., 1999) dose-dependently blocked the expression of social
interaction deficits in withdrawing animals. This effect seemed to be specific for anxiety-like
behavior in withdrawing animals, because there were no significant effects on locomotor
deficits in withdrawing rats or normal locomotor or social interaction behaviors in control rats.
Because the NMDA receptor antagonist ifenprodil was not active in ethanol-withdrawn rats in
the current study at any dose, it would appear that NMDA receptors are not exerting significant
effects on anxiety-like behavior during ethanol withdrawal. Ifenprodil was not active in either
the plus-maze or social interaction test, despite being used at or above a dose that is behaviorally
active against the diazepam withdrawal syndrome and hypoxia (Eraković et al., 1997; Tsuda
et al., 1998). This observation, combined with the anxiogenic-like response seen in control
rats, supports the suggestion that the drug is not likely to be a good anxiolytic prospect in
alcoholism. The drug also inhibited locomotor activity in control rats, but no differential effect
was seen in withdrawing rats treated with ifenprodil or vehicle. These results are important in
determining receptor targets relevant to expression of withdrawal signs because evidence
consistently shows that NMDA receptors play a role in action of glutamate receptor–mediated
hyperexcitability during withdrawal (Kumari & Ticku, 2000). In other studies, the competitive
NMDA receptor antagonists 2-amino-7-phosphonoheptanoic acid (AP-7) and D,L-(E)-amino-4-
methyl-5-phosphono-3-pentenoic acid (CGP 37849), but not the noncompetitive NMDA
receptor channel blocker MK-801, attenuated the plus-maze deficits during ethanol withdrawal
in the elevated plus-maze (Criswell et al., 1994; Gatch et al., 1999). These results support the
suggestion that glutamate action on this behavior during ethanol withdrawal depends on the
receptor subtype and the mechanism of receptor blockade.
In summary, results of experiments in the current study revealed anxiety-like behavior during
withdrawal from short-term ethanol intake that was attenuated by antagonists of
benzodiazepine, CRF, and 5-HT2C receptors, but not by antagonists of NMDA-type glutamate
or 5-HT3 receptors or an agonist of benzodiazepine type 1 receptors. These results support the
suggestion that multiple neuronal systems may contribute to the specific ethanol withdrawal
sign of anxiety and that anxiety can be manipulated in a pharmacologically selective manner.
These results are consistent with the general theoretical principle that negative reinforcement
(e.g., tension reduction, anxiety reduction, and alleviation of other signs and symptoms of acute
or chronic ethanol withdrawal) is a potentially important motivator of pathologic levels of
alcohol consumption (Cappell & LeBlanc, 1981; Hershon, 1977; Koob & Le Moal, 1997).
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Mean social interaction time and locomotor activity scores for control and ethanol-withdrawn
rats. For 17 days, rats were exposed to ethanol (8–12 g/kg/day), and their behavior was
subsequently tested between 5 and 6 h into withdrawal. Bars (means ± S.E.M.) that do not
share common letters are significantly different from each other (P < .05).
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Mean social interaction time and locomotor activity scores for control and ethanol-withdrawn
(ETW) rats treated with the 5-hydroxytryptamine (serotonin) 2C (5-HT2C) receptor antagonist
SB242084, the benzodiazepine receptor antagonist flumazenil (Flum), or the N-methyl-D-
aspartate (NMDA)–type glutamate receptor antagonist ifenprodil (Ifen). Rats were treated for
17 days with 7% (weight/volume) ethanol diet and tested between 5 and 6 h into withdrawal.
Bars (means ± S.E.M.) that do not share common letters are significantly different from each
other (P < .05). CMC = 0.5% solution of carboxymethylcellulose vehicle.
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Mean time in open arms and number of closed-arm entries in the elevated plus-maze test of
anxiety in ethanol-withdrawn (ETW) rats treated with vehicle [0.5% solution of
carboxymethylcellulose (CMC)], the benzodiazepine receptor antagonist flumazenil (Flum),
the 5-hydroxytryptamine (serotonin) 2C (5-HT2C) receptor antagonist SB242084, or the N-
methyl-D-aspartate (NMDA)–type glutamate receptor antagonist ifenprodil (Ifen). Rats were
treated for 17 days with 7% (weight/volume) ethanol diet and tested between 5 and 6 h into
withdrawal. Bars (means ± S.E.M.) that do not share common letters are significantly different
from each other (P < .05).
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Mean social interaction time and locomotor activity scores for control and ethanol-withdrawn
(ETW) rats treated with the 5-hydroxytryptamine (serotonin) 3 (5-HT3) receptor antagonist
MDL 72222 (MDL), the corticotropin-releasing factor (CRF) antagonist CRA1000, or the N-
methyl-D-aspartate (NMDA)–type glutamate receptor antagonist ifenprodil (Ifen). Rats were
treated for 17 days with 7% (weight/volume) ethanol diet and tested between 5 and 6 h into
withdrawal. Bars (means ± S.E.M.) that do not share common letters are significantly different
from each other (P < .05). CMC = 0.5% solution of carboxymethylcellulose vehicle.
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Mean social interaction time and locomotor activity scores for control and ethanol-withdrawn
(ETW) rats treated with vehicle [0.5% solution of carboxymethylcellulose (CMC)], the
benzodiazepine receptor antagonist flumazenil (Flum), the benzodiazepine receptor agonist
zolpidem (Zolp), and the N-methyl-D-aspartate (NMDA)–type glutamate receptor antagonist
ifenprodil (Ifen). Rats were treated for 17 days with 7% (weight/volume) ethanol diet and tested
between 5 and 6 h into withdrawal. Bars (means ± S.E.M.) that do not share common letters
are significantly different from each other (P < .05).
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Table 1
Effects of drugs that counteract withdrawal-induced social interaction deficits in control rats
Drug Social interaction (s) Line crossings
CMC vehicle (1 ml/kg) 31.5 ± 3.4 116 ± 12
SB242084 (1 mg/kg) 33.4 ± 6.1 129 ± 16
CRA1000 (1 mg/kg) 31.6 ± 5.7 121 ± 17
Flumazenil (5 mg/kg) 31.9 ± 3.5 85 ± 12*
Ifenprodil (5 mg/kg) 13.6 ± 3.2* 23 ± 6*
*
Significantly different from values for CMC vehicle (0.5% solution of carboxymethylcellulose).
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Table 2
Acute dose-related effects of drugs on time spent in social interaction and line crossings in rats withdrawn from
17 days of 7% (weight/volume) ethanol diet
Treatment Social interaction (s) Line crossings
Control diet 26.8 ± 1.8 95.9 ± 9.3
Ethanol diet 8.8 ± 1.8* 22.8 ± 6.3*
Ifenprodil (mg/kg)
2.5 13.9 ± 3.7* 21.5 ± 6.1*
5.0 6.8 ± 1.5* 22.7 ± 7.0*
10.0 8.3 ± 2.4* 14.2 ± 6.7*
Zolpidem (mg/kg)
1.5 7.8 ± 2.3* 12.3 ± 6.8*
3.0 12.5 ± 4.1* 37.0 ± 8.7*
MDL 72222 (mg/kg)
0.3 14.3 ± 3.6* 18.2 ± 4.2*
1.0 8.2 ± 2.2* 26.0 ± 5.6*
3.0 12.3 ± 5.7* 24.5 ± 7.4*
Flumazenil (mg/kg)
1.25 4.3 ± 1.2* 23.8 ± 6.7*
2.50 16.5 ± 1.8*,** 36.5 ± 10.0*
5.00 22.8 ± 3.0** 36.1 ± 5.5*
CRA1000 (mg/kg)
0.25 13.0 ± 3.0* 32.8 ± 9.8*
0.50 15.8 ± 3.0*,** 37.5 ± 13.0*
1.00 20.0 ± 3.9*,** 55.3 ± 15.2*
SB242084 (mg/kg)
0.25 6.0 ± 2.9* 55.3 ± 15.2*
0.50 11.3 ± 3.6* 26.7 ± 6.2*
1.00 21.5 ± 2.1** 52.0 ± 19.5*
*
Significantly different from values for control diet.
**
Significantly different from values for ethanol diet.
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